{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:14Z","timestamp":1794096014861,"version":"4.8.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery, and steroid-free remission. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant metabolic benefits for patients with type 2 diabetes mellitus (T2DM) and obesity. Hence, GLP1-RAs may improve clinical outcomes in patients with IBD, especially those with obesity. The objective was to systematically evaluate the impact of GLP1-RAs on clinical outcomes in patients with IBD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search was performed using the databases PubMed, Embase, Web of Science, and Cochrane Library from inception to March 15, 2025. Studies reporting outcomes related to GLP1-RAs in patients with IBD were included. Primary outcomes included weight loss and various IBD-related co-endpoints such as hospitalizations, surgery, corticosteroid use, and advanced therapy initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In total, 11 studies with 16\u2009242 patients with IBD treated with GLP1-RAs were included. Weight loss was achieved using semaglutide (\u22129.6 kg, 95% confidence interval [CI]: \u221212.0; \u22127.2), liraglutide (\u22129.4 kg, 95% CI: \u221213.0; \u22125.8), and tirzepatide (\u221211.8 kg, 95% CI: \u221218.3; \u22125.4) after 3 months of follow-up. In meta-analyses, GLP1-RAs were associated with lower risk of surgery for effect sizes (logHR: 0.61 [95% CI: 0.44-0.84], I\u20092\u2009=\u20090%) and event frequencies (odds ratio [OR]: 0.46 [95% CI: 0.32-0.67], I\u20092\u2009=\u200942%). Sensitivity analysis for body mass index (BMI) showed a lower risk of hospitalizations and surgery in patients with obesity (BMI\u2009\u2265\u200930).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Patients with IBD and obesity using GLP1-RAs were able to achieve significant weight loss and had lower risks of surgery and hospitalizations. Our findings require confirmation in prospective trials of GLP1-RAs in IBD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf181","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T12:11:25Z","timestamp":1759925485000},"source":"Crossref","is-referenced-by-count":21,"title":["Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"19","author":[{"given":"Ahmed B","family":"Bayoumy","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8088-5025","authenticated-orcid":false,"given":"Lindsay M","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Harvard Medical School, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3436-9784","authenticated-orcid":false,"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine , St Louis, MI,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-7712","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network , Pittsburgh, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Sehgal","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Thomas Jefferson University Hospital , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"uri","family":"Gorelik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Rambam Health Care Campus , Haifa,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0376-4930","authenticated-orcid":false,"given":"Haggai","family":"Bar-Yoseph","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Rambam Health Care Campus , Haifa,","place":["Israel"]},{"name":"The Ruth & Bruce Rappaport Faculty of Medicine, Technion-Israel institute of technology , Haifa,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Villumsen","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital , The Capital Region, Copenhagen,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris J J","family":"Mulder","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk J","family":"Stenvers","sequence":"additional","affiliation":[{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Amsterdam,","place":["The Netherlands"]},{"name":"Department of Endocrinology and Metabolism, Amsterdam University Medical Center, University of Amsterdam , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten E","family":"Tushuizen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Leiden University Medical Center , Leiden,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanne K H","family":"de Boer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Amsterdam University Medical Center , Amsterdam,","place":["The Netherlands"]},{"name":"Amsterdam Gastroenterology Endocrinology Metabolism Research Institute , Amsterdam,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"2025120116470919100_jjaf181-B1","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"2025120116470919100_jjaf181-B2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00210-019-01698-z","article-title":"Role of glucagon-like peptides in inflammatory bowel diseases-current knowledge and future perspectives","volume":"392","author":"Zatorski","year":"2019","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025120116470919100_jjaf181-B3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41572-020-0205-x","article-title":"Ulcerative colitis","volume":"6","author":"Kobayashi","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025120116470919100_jjaf181-B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41572-020-0156-2","article-title":"Crohn\u2019s disease","volume":"6","author":"Roda","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"2025120116470919100_jjaf181-B5","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.1007\/s00210-024-03631-5","article-title":"Protective effect of Dulaglutide, a GLP1 agonist, on acetic acid-induced ulcerative colitis in rats: involvement of GLP-1, TFF-3, and TGF-\u03b2\/PI3K\/NF-\u03baB signaling pathway","volume":"398","author":"Mahdy","year":"2025","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025120116470919100_jjaf181-B6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/imm.13784","article-title":"GLP-1 receptor agonists alleviate colonic inflammation by modulating intestinal microbiota and the function of group 3 innate lymphoid cells","volume":"172","author":"Sun","year":"2024","journal-title":"Immunology"},{"key":"2025120116470919100_jjaf181-B7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","article-title":"GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use","volume":"12","author":"Arvanitakis","year":"2023","journal-title":"Curr Obes Rep"},{"key":"2025120116470919100_jjaf181-B8","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2025120116470919100_jjaf181-B9","doi-asserted-by":"publisher","first-page":"15582","DOI":"10.1038\/s41598-019-52103-x","article-title":"Metabolic and gut microbiome changes following GLP-1 or dual GLP-1\/GLP-2 receptor agonist treatment in diet-induced obese mice","volume":"9","author":"Madsen","year":"2019","journal-title":"Sci Rep"},{"key":"2025120116470919100_jjaf181-B10","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/gutjnl-2024-331914","article-title":"Heavy arch: from inflammatory bowel diseases to metabolic disorders","volume":"73","author":"Adolph","year":"2024","journal-title":"Gut"},{"key":"2025120116470919100_jjaf181-B11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nrgastro.2016.181","article-title":"Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes","volume":"14","author":"Singh","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2025120116470919100_jjaf181-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14740338.2025.2465870","article-title":"Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis","author":"Alfehaid","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"2025120116470919100_jjaf181-B13","author":"A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight"},{"key":"2025120116470919100_jjaf181-B14","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1007\/s10620-025-08964-6","article-title":"Tolerability and effectiveness of glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease","volume":"70","author":"Clarke","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2025120116470919100_jjaf181-B15","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1007\/s10620-025-09052-5","article-title":"Obesity is associated with inferior clinical treatment outcomes in inflammatory bowel disease: a nationwide dutch registry study","volume":"70","author":"Oomkens","year":"2025","journal-title":"Dig Dis Sci"},{"key":"2025120116470919100_jjaf181-B16","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cgh.2018.07.004","article-title":"Obesity is independently associated with higher annual burden and costs of hospitalization in patients with inflammatory bowel diseases","volume":"17","author":"Nguyen","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025120116470919100_jjaf181-B17","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1111\/apt.18513","article-title":"Obesity is associated with worsened outcomes in patients with ulcerative colitis on advanced therapies: a propensity matched cohort study from the U.S","volume":"61","author":"Desai","year":"2025","journal-title":"Aliment Pharmacol Ther."},{"key":"2025120116470919100_jjaf181-B18","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/mog.0000000000001025","article-title":"Reviewing the impact of obesity on inflammatory bowel disease and considerations for optimizing management","volume":"40","author":"Ghusn","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"2025120116470919100_jjaf181-B19","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2023.06.036","article-title":"Higher intra-abdominal visceral adipose tissue mass is associated with lower rates of clinical and endoscopic remission in patients with inflammatory bowel diseases initiating biologic therapy: results of the constellation study","volume":"165","author":"Yarur","year":"2023","journal-title":"Gastroenterology"},{"key":"2025120116470919100_jjaf181-B20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2025120116470919100_jjaf181-B21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"2025120116470919100_jjaf181-B22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.14309\/ajg.0000000000003208","article-title":"Safety and effectiveness of glucagon-like peptide-1 receptor agonists in inflammatory bowel disease","volume":"120","author":"Anderson","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2025120116470919100_jjaf181-B23","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/ibd\/izae276","article-title":"Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease-a danish nationwide cohort study","volume":"31","author":"Nielsen","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025120116470919100_jjaf181-B24","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1093\/ecco-jcc\/jjae160","article-title":"GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN","volume":"19","author":"Gorelik","year":"2025","journal-title":"J Crohns Colitis"},{"key":"2025120116470919100_jjaf181-B25","doi-asserted-by":"publisher","first-page":"4437","DOI":"10.1007\/s10620-024-08720-2","article-title":"Efficacy and safety of GLP-1 agonists on metabolic parameters in non-diabetic patients with inflammatory bowel disease","volume":"69","author":"St-Pierre","year":"2024","journal-title":"Dig Dis Sci"},{"key":"2025120116470919100_jjaf181-B26","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1093\/ibd\/izae250","article-title":"GLP-1 receptor agonists confer no increased rates of IBD exacerbation among patients with IBD","volume":"31","author":"Levine","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025120116470919100_jjaf181-B27","doi-asserted-by":"publisher","first-page":"478","DOI":"10.17235\/reed.2024.10305\/2024","article-title":"Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease","volume":"116","author":"Ramos Belinch\u00f3n","year":"2024","journal-title":"Rev Esp Enferm Dig"},{"key":"2025120116470919100_jjaf181-B28","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120116470919100_jjaf181-B29","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/ibd\/izae090","article-title":"Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity","volume":"31","author":"Desai","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2025120116470919100_jjaf181-B30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.cgh.2024.12.017","article-title":"Safety and clinical effectiveness of GLP1 receptor agonists in inflammatory bowel disease patients","volume":"23","author":"Sehgal","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025120116470919100_jjaf181-B31","doi-asserted-by":"publisher","first-page":"100979","DOI":"10.1016\/j.eclinm.2021.100979","article-title":"GLP-1 based therapies and disease course of inflammatory bowel disease","volume":"37","author":"Villumsen","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025120116470919100_jjaf181-B32","doi-asserted-by":"publisher","first-page":"S-1424","DOI":"10.1016\/S0016-5085(24)03727-2","article-title":"Tu1826 impact of GLP-1 receptor agonist on clinical outcomes in patients with Crohn\u2019s disease and ulcerative colitis: insights from a large-scale cohort study","volume":"166","author":"Niu","year":"2024","journal-title":"Gastroenterology"},{"key":"2025120116470919100_jjaf181-B33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.5217\/ir.2021.00046","article-title":"A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations","volume":"20","author":"Dahiya","year":"2022","journal-title":"Intest Res"},{"key":"2025120116470919100_jjaf181-B34","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1111\/apt.14665","article-title":"High body mass index is associated with increased risk of treatment failure and surgery in biologic-treated patients with ulcerative colitis","volume":"47","author":"Kurnool","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"2025120116470919100_jjaf181-B35","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12944-023-01874-4","article-title":"Association between body fat composition and disease duration, clinical activity, and intravenous corticosteroid-induced response in inflammatory bowel disease","volume":"22","author":"He","year":"2023","journal-title":"Lipids Health Dis"},{"key":"2025120116470919100_jjaf181-B36","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1002\/cpt.2430","article-title":"Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes","volume":"111","author":"Faillie","year":"2022","journal-title":"Clin Pharmacol Ther."},{"key":"2025120116470919100_jjaf181-B37","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.apsb.2023.02.020","article-title":"A potentially serious adverse effect of GLP-1 receptor agonists","volume":"13","author":"Lu","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"2025120116470919100_jjaf181-B38","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"2025120116470919100_jjaf181-B39","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.cgh.2023.08.034","article-title":"Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: scandinavian cohort study","volume":"22","author":"Ueda","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025120116470919100_jjaf181-B40","doi-asserted-by":"publisher","first-page":"S-518","DOI":"10.1016\/S0016-5085(24)01662-7","article-title":"Sa1777 IBD patients concomitantly treated with GLP1 agonists had fewer hospitalizations and disease related complications: a US cohort propensity-matched study","volume":"166","author":"Alchirazi","year":"2024","journal-title":"Gastroenterology"},{"key":"2025120116470919100_jjaf181-B41","doi-asserted-by":"publisher","DOI":"10.3390\/ph17020199","article-title":"Glucagon-like peptide-1 receptor agonists associated gastrointestinal adverse events: a cross-sectional analysis of the national institutes of health all of us cohort","volume":"17","author":"Aldhaleei","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025120116470919100_jjaf181-B42","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40264-023-01392-3","article-title":"Drug-drug interactions between glucagon-like peptide 1 receptor agonists and oral medications: a systematic review","volume":"47","author":"Calvarysky","year":"2024","journal-title":"Drug Saf"},{"key":"2025120116470919100_jjaf181-B43","doi-asserted-by":"publisher","first-page":"e01544","DOI":"10.14309\/crj.0000000000001544","article-title":"Dramatic changes in thiopurine metabolite levels in a patient with inflammatory bowel disease treated with tirzepatide for weight loss","volume":"11","author":"Klein","year":"2024","journal-title":"ACG Case Rep J"},{"key":"2025120116470919100_jjaf181-B44","author":"A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Crohn\u2019s Disease and Obesity or Overweight"},{"key":"2025120116470919100_jjaf181-B45","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jama.2023.13872","article-title":"Patents and regulatory exclusivities on GLP-1 receptor agonists","volume":"330","author":"Alhiary","year":"2023","journal-title":"JAMA"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf181\/64612829\/jjaf181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/10\/jjaf181\/64612829\/jjaf181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/10\/jjaf181\/64612829\/jjaf181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T21:47:15Z","timestamp":1764625635000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf181\/8280408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf181","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]},"article-number":"jjaf181"}}